Literature DB >> 1552713

EDRF role in renal function and blood pressure of normal rats and rats with obstructive uropathy.

A A Reyes1, D Martin, S Settle, S Klahr.   

Abstract

There is a decrease in glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) and an increase in mean arterial pressure (MAP) and renal vascular resistance (RVR) after release of bilateral ureteral obstruction (BUO) of 24 hours duration. The present studies examine the role of endothelium-derived relaxing factor (EDRF) in the renal hemodynamics of sham-operated rats (SOR) and rats in which BUO of 24 hours duration was unilaterally released. In both groups of rats, renal function and blood pressure were measured in the awake state under basal conditions and after administration of L-arginine (L-arg), the substrate for EDRF synthesis, followed by NwNAME, an L-arg antagonist, or after administration of NwNAME followed by L-arg. Administration of L-arg alone to SOR did not affect renal function, MAP or RVR. In SOR given L-arg and then NwNAME, there was significantly decreased GFR and ERPF and increased MAP and RVR. When NwNAME was given initially, similar changes were obtained, and these were reversed by the administration of L-arg. Rats given L-arginine immediately after unilateral release of BUO of 24 hours duration had significantly greater GFR and ERPF values and lower MAP and RVR than temporal controls. NwNAME given to BUO rats decreased renal function further and increased MAP and RVR. We found a dose-dependent increase in GFR and ERPF and a dose-dependent decrease in MAP and RVR in both SOR and rats with BUO given increasing amounts of L-arg. There was also a dose-dependent decrease in GFR and ERPF and an increase in MAP and RVR in SOR and rats with BUO given increasing amounts of NwNAME or NGNMA, the two different antagonists of L-arg. In another set of experiments, SOR and rats with BUO were given L-arg preoperatively (that is, 24 hr prior to study). Both groups of rats had significantly higher GFR and ERPF values and lower MAP and RVR than control rats. Sham-operated rats given NwNAME 24 hours prior to study had significantly lower GFR and ERPF and higher MAP and RVR than untreated rats. Rats with BUO given NwNAME prior to obstruction had no measurable renal function and had significantly higher values for MAP after release of obstruction. These studies confirm the role of L-arg administration, and presumably EDRF, in the regulation of MAP and renal function in sham-operated rats. The results of this study also suggest decreased availability of arginine for EDRF synthesis in rats with BUO.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1552713     DOI: 10.1038/ki.1992.56

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  5 in total

1.  Increased production of nitric oxide in patients with hemorrhagic fever with renal syndrome--relation to arterial hypotension and tumor necrosis factor.

Authors:  M Linderholm; P H Groeneveld; A Tärnvik
Journal:  Infection       Date:  1996 Sep-Oct       Impact factor: 3.553

2.  L-arginine may mediate the therapeutic effects of low protein diets.

Authors:  I Narita; W A Border; M Ketteler; E Ruoslahti; N A Noble
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

Review 3.  Mechanisms of renal injury and progression of renal disease in congenital obstructive nephropathy.

Authors:  Robert L Chevalier; Barbara A Thornhill; Michael S Forbes; Susan C Kiley
Journal:  Pediatr Nephrol       Date:  2009-10-21       Impact factor: 3.714

4.  The effect of L-arginine on arterial stiffness and oxidative stress in chronic kidney disease.

Authors:  S K Annavarajula; K V Dakshinamurty; M U R Naidu; C Prabhakar Reddy
Journal:  Indian J Nephrol       Date:  2012-09

5.  Effect of L-arginine and L-NAME on Kidney Tissue Damage in Rats after 24 h of Bilateral Ureteral Obstruction.

Authors:  Shahnaz Amani Tirani; Zahra Pezeshki; Mehdi Nematbakhsh; Hamid Nasri; Ardeshir Talebi
Journal:  Int J Prev Med       Date:  2015-07-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.